Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

Soft-tissue fat tumours: differentiating malignant from benign using proton density fat fraction quantification MRI.

Skorpil M, Rydén H, Berglund J, Brynolfsson P, Brosjö O, Tsagozis P.

Clin Radiol. 2019 Apr 15. pii: S0009-9260(19)30073-X. doi: 10.1016/j.crad.2019.01.011. [Epub ahead of print]

PMID:
31000331
2.

An immunosuppressive macrophage profile attenuates the prognostic impact of CD20-positive B cells in human soft tissue sarcoma.

Tsagozis P, Augsten M, Zhang Y, Li T, Hesla A, Bergh J, Haglund F, Tobin NP, Ehnman M.

Cancer Immunol Immunother. 2019 Mar 16. doi: 10.1007/s00262-019-02322-y. [Epub ahead of print]

PMID:
30879106
3.

Ewing sarcoma of the mobile spine; predictive factors for survival, neurological function and local control. A Scandinavian sarcoma group study with a mean follow-up of 12 years.

Hesla AC, Bruland ØS, Jebsen N, Styring E, Eriksson S, Tsagozis P.

J Bone Oncol. 2018 Dec 26;14:100216. doi: 10.1016/j.jbo.2018.100216. eCollection 2019 Feb.

4.

What Factors Are Associated With Implant Breakage and Revision After Intramedullary Nailing for Femoral Metastases?

Willeumier JJ, Kaynak M, van der Zwaal P, Meylaerts SAG, Mathijssen NMC, Jutte PC, Tsagozis P, Wedin R, van de Sande MAJ, Fiocco M, Dijkstra PDS.

Clin Orthop Relat Res. 2018 Sep;476(9):1823-1833. doi: 10.1007/s11999.0000000000000201.

PMID:
30566108
5.

High complication rate after extendible endoprosthetic replacement of the proximal tibia: a retrospective study of 42 consecutive children.

Tsagozis P, Parry M, Grimer R.

Acta Orthop. 2018 Dec;89(6):678-682. doi: 10.1080/17453674.2018.1534320. Epub 2018 Oct 29.

6.

Preoperative radiotherapy of soft-tissue sarcomas: surgical and radiologic parameters associated with local control and survival.

Tsagozis P, Brosjö O, Skorpil M.

Clin Sarcoma Res. 2018 Oct 5;8:19. doi: 10.1186/s13569-018-0106-x. eCollection 2018.

7.

Spinal metastasis with neurologic deficits.

Tsagozis P, Bauer HCF.

Acta Orthop. 2018 Apr;89(2):229-233. doi: 10.1080/17453674.2017.1412193. Epub 2017 Dec 12.

8.

Outcome of surgery for primary and recurrent desmoid-type fibromatosis. A retrospective case series of 174 patients.

Tsagozis P, Stevenson JD, Grimer R, Carter S.

Ann Med Surg (Lond). 2017 Mar 22;17:14-19. doi: 10.1016/j.amsu.2017.03.023. eCollection 2017 May.

9.

Improved Prognosis for Patients with Ewing Sarcoma in the Sacrum Compared with the Innominate Bones: The Scandinavian Sarcoma Group Experience.

Hesla AC, Tsagozis P, Jebsen N, Zaikova O, Bauer H, Brosjö O.

J Bone Joint Surg Am. 2016 Feb 3;98(3):199-210. doi: 10.2106/JBJS.O.00362. Erratum in: J Bone Joint Surg Am. 2016 Apr 6;98(7):e29.

PMID:
26842410
10.

Current Strategies for the Treatment of Aneurysmal Bone Cysts.

Tsagozis P, Brosjö O.

Orthop Rev (Pavia). 2015 Dec 28;7(4):6182. doi: 10.4081/or.2015.6182. eCollection 2015 Dec 28. Review.

11.

Femoral Metastasis from Penile Carcinoma: Report of 2 Cases.

Braumann L, Tsagozis P, Wedin R, Brosjö O.

Case Rep Urol. 2015;2015:583851. doi: 10.1155/2015/583851. Epub 2015 Oct 22.

12.

Reconstruction of metastatic acetabular defects using a modified Harrington procedure.

Tsagozis P, Wedin R, Brosjö O, Bauer H.

Acta Orthop. 2015;86(6):690-4. doi: 10.3109/17453674.2015.1077308. Epub 2015 Jul 28.

13.

Prognostic factors and follow-up strategy for superficial soft-tissue sarcomas: Analysis of 622 surgically treated patients from the scandinavian sarcoma group register.

Tsagozis P, Bauer HC, Styring E, Trovik CS, Zaikova O, Brosjö O.

J Surg Oncol. 2015 Jun;111(8):951-6. doi: 10.1002/jso.23927. Epub 2015 Jun 3.

PMID:
26040651
14.

Giant hydatid cyst of the pelvis, femur and retroperitoneal space: surgical treatment with extended hemipelvectomy.

Tsagozis P, Brosjö O.

BMJ Case Rep. 2015 May 12;2015. pii: bcr2015209715. doi: 10.1136/bcr-2015-209715.

15.

Treatment of an aggressive aneurysmal bone cyst with percutaneous injection of polidocanol: a case report.

Brosjö O, Tsagozis P.

J Med Case Rep. 2014 Dec 20;8:450. doi: 10.1186/1752-1947-8-450.

16.

The use of megaprostheses for reconstruction of large skeletal defects in the extremities: a critical review.

Gkavardina A, Tsagozis P.

Open Orthop J. 2014 Oct 17;8:384-9. doi: 10.2174/1874325001408010384. eCollection 2014.

17.

All trans-retinoic acid abrogates the pro-tumorigenic phenotype of prostate cancer tumor-associated macrophages.

Tsagozis P, Augsten M, Pisa P.

Int Immunopharmacol. 2014 Nov;23(1):8-13. doi: 10.1016/j.intimp.2014.07.037. Epub 2014 Aug 14.

PMID:
25130608
18.

Sclerotherapy with polidocanol for treatment of aneurysmal bone cysts.

Brosjö O, Pechon P, Hesla A, Tsagozis P, Bauer H.

Acta Orthop. 2013 Oct;84(5):502-5. doi: 10.3109/17453674.2013.850013. Epub 2013 Oct 31.

19.

Femoral stem displacement in a patient suffering recurrent dislocations after hip hemiarthroplasty: case report.

Tsagozis P, Henriksson M, Ioannidis I.

Open Orthop J. 2011;5:400-2. doi: 10.2174/1874325001105010400. Epub 2011 Dec 30.

20.

Tumor-specific bacteriophages induce tumor destruction through activation of tumor-associated macrophages.

Eriksson F, Tsagozis P, Lundberg K, Parsa R, Mangsbo SM, Persson MA, Harris RA, Pisa P.

J Immunol. 2009 Mar 1;182(5):3105-11. doi: 10.4049/jimmunol.0800224.

21.

CXCL14 is an autocrine growth factor for fibroblasts and acts as a multi-modal stimulator of prostate tumor growth.

Augsten M, Hägglöf C, Olsson E, Stolz C, Tsagozis P, Levchenko T, Frederick MJ, Borg A, Micke P, Egevad L, Ostman A.

Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3414-9. doi: 10.1073/pnas.0813144106. Epub 2009 Feb 13.

22.

Zoledronic acid modulates antitumoral responses of prostate cancer-tumor associated macrophages.

Tsagozis P, Eriksson F, Pisa P.

Cancer Immunol Immunother. 2008 Oct;57(10):1451-9. doi: 10.1007/s00262-008-0482-9. Epub 2008 Feb 23.

PMID:
18297280
23.

Interference of macrophage migration inhibitory factor expression in a mouse melanoma inhibits tumor establishment by up-regulating thrombospondin-1.

Culp WD, Tsagozis P, Burgio M, Russell P, Pisa P, Garland D.

Mol Cancer Res. 2007 Dec;5(12):1225-31. doi: 10.1158/1541-7786.MCR-07-0229.

24.

Cellular FLIP long isoform transgenic mice overcome inherent Th2-biased immune responses to efficiently resolve Leishmania major infection.

Tseveleki V, Tsagozis P, Koutsoni O, Dotsika E, Probert L.

Int Immunol. 2007 Oct;19(10):1183-9. Epub 2007 Sep 18.

PMID:
17878261
25.

Current perspectives in the treatment of advanced prostate cancer.

Valdespino V, Tsagozis P, Pisa P.

Med Oncol. 2007;24(3):273-86. Review.

PMID:
17873302
26.

Function of CD8+ T lymphocytes in a self-curing mouse model of visceral leishmaniasis.

Tsagozis P, Karagouni E, Dotsika E.

Parasitol Int. 2005 Jun;54(2):139-46.

PMID:
15866476
27.

The impact of a successful anti-myxosporean treatment on the phagocyte functions of juvenile and adult Sparus aurata L.

Karagouni E, Athanassopoulou F, Tsagozis P, Ralli E, Moustakareas T, Lytra K, Dotsika E.

Int J Immunopathol Pharmacol. 2005 Jan-Mar;18(1):121-32.

PMID:
15698517
28.

Dendritic cells pulsed with peptides of gp63 induce differential protection against experimental cutaneous leishmaniasis.

Tsagozis P, Karagouni E, Dotsika E.

Int J Immunopathol Pharmacol. 2004 Sep-Dec;17(3):343-52.

PMID:
15461868

Supplemental Content

Loading ...
Support Center